News

NIH-led effort – including ISB – launches Big Data portal for Alzheimer’s drug discovery

The National Institutes of Health announced the launch of a new Alzheimer’s Big Data portal, which includes the first wave of data for use by the research community. This portal is the result of the Accelerating Medicines Partnership (AMP) program, which focuses on facilitating collaboration among government agencies, academia and industry in order to translate research more quickly to therapies.

The launch of the AMP Alzeheimers Disease Knowledge Portal is the first major release of the project, to which a consortium of teams contribute data and analysis: Eric Schadt, Ph.D., Icahn School of Medicine at Mount Sinai, New York; Philip De Jager, M.D., Ph.D., Eli and Edythe L. Broad Institute of MIT and Harvard, Boston; Todd Golde, M.D., Ph.D., University of Florida, Gainesville; and Alan Levey, M.D., Ph.D., Emory University, Atlanta. Researchers from Rush University, Chicago; Mayo Clinic, Jacksonville, Fla.; Institute for Systems Biology, Seattle; the University of California, Los Angeles and a number of other academic centers are also participating. ISB’s Price Lab is participating in this project through a collaboration with the University of Florida.

Ben Heavner, a research scientist in the Price Lab, is leading the bioinformatics work, which involves translating raw data into a uniform format and then uploading to the data portal. “This is a huge step for open science,” Ben said. “This portal offers access to thousands of data sets pre-publication so that all researchers have the opportunity to make the discoveries that will lead to better therapeutics .”

Read more about the NIH’s $45M in grants to support Alzheimer’s research.

Recent Articles

  • Priyanka Baloni

    Bile Acids Provide More Evidence of the Gut Microbiome’s Effect on Alzheimer’s Disease

    ISB researchers and their collaborators are looking beyond the one-drug, one-solution approach that has thus far failed in Alzheimer’s disease research. Instead, they are focusing on other promising research avenues, such as the possible role of the gut microbiome in dementia.

  • Overall composition of gut microbiome in participants

    Variations in the Microbiome Associated with Health, Disease

    ISB researchers examined the associations between the gut microbiomes of about 3,400 people and roughly 150 host characteristics. The team looked at diet, medication use, clinical blood markers, and other lifestyle and clinical factors, and found evidence that variations of the gut microbiome are associated with health and disease.

  • Andrew Magis

    ISB Researchers Identify Signals of Metastatic Cancer Years Prior to Diagnosis

    By analyzing blood plasma samples taken at several time points, ISB researchers have identified specific proteins that persistently presented as outliers and signaled metastatic cancer well before patients were diagnosed. The findings were published in the journal Scientific Reports.